BCLI News Alert Brainstorm Cell Ther (BCLI) 0.2825 09/26/2014

New Post Public Reply Private Reply Replies (0) Message Board

Sep 26, 2014 at 5:22 AM

Brainstorm Cell Ther (BCLI) 0.2825 $BCLI

BrainStorm completes one for 15 reverse common stock split
M2 - Tue Sep 16, 6:43AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLID) on Monday reported a one for 15 reverse split of its issued and outstanding common stock for the uplisting of its common stock on the NASDAQ Capital Market.

BrainStorm Announces Completion of Reverse Split of Common Stock, a Key Step for Uplisting on the NASDAQ
ACCESSWIRE - Tue Sep 16, 5:29AM CDT
NEW YORK, NY and PETACH TIKVAH, ISRAEL / ACCESSWIRE / September 16, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI) (OTCQB: BCLID), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that at 11:59 p.m. on September 15, 2014, (the "Effective Date"

, it effected a one (1) for fifteen (15) reverse split of its issued and outstanding common stock (the "Reverse Split"

as a step toward the Company's intention to have its common stock listed on the NASDAQ Capital Market.

BrainStorm Provides Update on NASDAQ Uplisting Process
Marketwire - Tue Sep 09, 5:29AM CDT
Brainstorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that on September 15, 2014, it plans to effect a 1 for 15 reverse split of its issued and outstanding common stock as part of its intended plan to pursue a stock listing on the NASDAQ Capital Market.

BrainStorm to Present at the Rodman and Renshaw 16th Annual Global Investment Conference
ACCESSWIRE - Thu Sep 04, 8:21AM CDT
NEW YORK, NY and PETACH TIKVAH, ISRAEL / ACCESSWIRE / September 4, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate overview of BrainStorm and NurOwn(TM), its proprietary stem cell platform currently in a phase 2 trial in Amyotrophic Lateral Sclerosis. Details of the presentation are as follows:

BrainStorm Granted European Patent Covering its Stem Cells for the Treatment of CNS Diseases
ACCESSWIRE - Wed Sep 03, 7:46AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / September 3, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the European Patent Office (EPO) has granted the company patent number EP1893747, entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases." The European Patent Application will be published in the European Patent Bulletin 14/36 on September 3, 2014. This patent covers a method of production of the company's proprietary NurOwn™ technology, which consists of mesenchymal stem cells induced to secrete large quantities of neurotrophic factors, for use in the treatment of neurodegenerative diseases.

FDA Clears Mayo Clinic for Manufacture of NurOwn and Participation in BrainStorm's Phase 2 ALS Trial
ACCESSWIRE - Mon Aug 18, 7:13AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel /ACCESSWIRE / August 18, 2014 / BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Mayo Clinic Human Cellular Therapy Laboratory in Rochester, Minn. for production of NurOwn™, BrainStorm's proprietary autologous mesenchymal stem cells secreting neurotrophic factors (MSC-NTF). BrainStorm will continue working with the Mayo clinical team to complete the necessary steps to allow the site to begin enrolling subjects into its ongoing phase 2 study of NurOwn™, which is designed to evaluate the safety and efficacy of the transplantation of or NurOwn™ in patients with Amyotrophic Lateral Sclerosis (ALS).

BrainStorm Receives Notice of Allowance on US Patent
ACCESSWIRE - Mon Jul 28, 8:47AM CDT
NEW YORK, NY and PETACH TIKVAH, Israel / ACCESSWIRE / July 28, 2014 / BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, received Notice of Allowance from the United States Patent Office for Patent Application 12/994,761, titled "Mesenchymal Stem Cells for the Treatment of CNS Diseases."

BrainStorm Announces that University of Massachusetts Memorial Medical Center to Begin Enrolling Patients in Phase 2 ALS Clinical Trial
eTeligis - Tue Jul 15, 10:04AM CDT
Petach Tikvah, Israel, New York, NY, United States, via eTeligis Inc., 07/15/2014 - - BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the University of Massachusetts (UMass) Memorial Medical Center in Worcester, MA will begin enrolling patients into the Company's randomized, double-bling placebo-controlled phase 2 clinical trial in Amyotrophic Lateral Sclerosis (ALS). UMass Memorial is the second site to become active of the three sites participating in this trial. The other two clinical sites participating in the multi-center trial are Massachusetts General Hospital (MGH), which began enrolling patients into the trial last month, and the Mayo Clinic, which is expected to become active in the third quarter of 2014. The Dana Farber Cancer Institute's Connell and O'Reilly Cell Manipulation Core Facility will manufacture NurOwn cells for MGH and UMass Memorial.

BrainStorm publishes study of preclinical multidose in mice of NurOwn
M2 - Fri Jul 11, 7:01AM CDT
Adult stem cell company BrainStorm Cell Therapeutics (OTCQB:BCLI) announced on Friday that it has published a preclinical study about the safety of single and repeated intramuscular administration of NurOwn, its proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors, in the Clinical and Translational Medicine journal.

BrainStorm Announces Publication of Preclinical Multidose Study of NurOwn
Marketwire - Fri Jul 11, 6:08AM CDT
BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today publication of an important preclinical study in the journal Clinical and Translational Medicine. This paper describes the safety of single and repeated intramuscular administration of NurOwn, the Company's proprietary mesenchymal stem cells that are induced to secrete a variety of neurotrophic factors. NurOwn is in clinical development for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) and has demonstrated efficacy in preclinical models of a variety of neurodegenerative diseases, including Parkinson's disease, Huntingon's disease and multiple sclerosis. The results published today are important because they establish that repeated doses of NurOwn are safe in mice and more specifically, that mice generate only minimal immune response after repeated exposure to NurOwn, which are human cells. These data will help support the use of multiple doses of NurOwn in future clinical trials.

OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell Therapeutics, Inc., Advanced Cell Technology, Inc.
PR Newswire Europe - Tue Jul 01, 7:01AM CDT
LONDON, July 1, 2014 /PRNewswire/ --

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

7-Eleven Heats Up Breakfast with Cheetos Taco

When Breakfast Gets a Fiery Makeover If you're craving breakfast with a side of heat, 7-Eleven's latest menu might just wake you up faster than a double espresso. Their newest collaboration with Cheetos Flamin' Hot is painting breakfast red at Laredo Taco Company, offering a lineup that's got tongues wagging and mouths watering. "After the response to our first Cheetos...

Battery Testing Market to Reach $45 Billion by 2033

There's a gold rush happening in the battery testing market, as ambitious as any I've seen in my trading years. The market's taking off faster than a Wall Street trader on a bull market open, projected to skyrocket from $13.03 billion in 2026 to $45.06 billion by 2033. That's a hefty 19.4% compound annual growth rate, a pace that'll have big money and new players...

Canada's LNG Ambition: A Trillion-Dollar Gamble

The Push for the Third Largest LNG Exporter Canada's got massive ambitions, setting its sights on becoming the world's third largest exporter of liquefied natural gas (LNG) by 2050. It's no small feat, but if pulled off, it's bound to shake the market. The country expects to generate nearly C$1 trillion in investments and bring forth a whopping 250,000 jobs annually....

Tellus Raises APY to 8.00% Amid Inflation Crunch

Tellus Offers a Boost for Savers Battling Inflation Well, hotshot, if you thought the days of high returns on savings were long gone, tell that to Tellus. This proptech outfit just upped its Reserve Account annual percentage yield (APY) to a juicy 8.00%. That's a damn sight better than the pittance you'll get parking funds elsewhere. Just look at the numbers—consumer...

Navigating Funeral Arrangements: A Straightforward Guide

When the reaper comes knocking, families are left juggling grief and logistics—it ain't easy. Jake Leonetti from Lewis Funeral Chapel in Bremerton, Washington, has been in the trenches long enough to know the drill. His insights might just make those funeral arrangements a bit smoother, so let's cut to the chase. First Order of Business: Contact a Funeral Director First...

Eli Radiopharma Clinches Big Series A, Eyes Milestones

Making Waves in Radiopharmaceuticals Some days, it's not just about the numbers—it’s about the shift in an entire field. Eli Radiopharma just closed a grand RMB 400 million Series A financing, paving a path that could redefine radiopharmaceuticals. Kinfolk over at Huagai Capital led the charge, teaming up with Bayland Capital and a throng of other backers. They’re...

Granite Market Booms: Key Growth Insights 2026–2031

Granite Industry: Chunks of Opportunity Throw a rock, and you’re bound to hit a project that’s using granite somewhere. The market for this tough-as-nails natural stone is projected to grow to USD 24.03 billion by 2031, up from USD 18.94 billion in 2025. That’s according to Mordor Intelligence, which says we’re looking at a 4.25% CAGR during 2026-2031....

Avoid Pitfalls: Key Steps for Injury Claims Success

For anyone in West Virginia nursing wounds and pondering a lawsuit, it's crucial to sidestep the landmines that could blow your case out of the water before it even reaches a courtroom. Understanding Timing and Documentation Right off the bat, Frank Walker, a seasoned attorney in personal injury, highlights the dangers of delaying medical treatment. This mistake leaves a...

Mindmatrix and Bodine and Co. Join Forces for Success

Forging a Path Toward Partner Success Aligning tech and strategy is one thing businesses often fumble—at least, that's my take from this latest team-up between Mindmatrix and Bodine and Co. These folks are pairing an AI powerhouse with a customer experience veteran. Sounds like they're onto something big about pushing partners to actually perform. Gap-Busting Approach...

MGS Extends Engagement for BECI Power Line Project

The power game isn't always about flipping switches, my friends. With Midcontinent Grid Solutions (MGS), we're seeing another round of crowd-pleasing playacting as they pump the brakes on the BECI Project. New timeline, new promises—same old story. Investors, environmentalists, and citizens alike are watching this one unfold with a glass of iced tea and crossed fingers....